Mazdutide: Research Status, Identity, and Clinical Trial Landscape

What mazdutide is

Mazdutide is a synthetic peptide compound identified in chemical databases under PubChem CID 167312357. It has a large molecular structure with a molecular weight near 4,476 daltons, consistent with a multi-peptide chain built for extended biological activity. No regulatory agency has approved a drug label for mazdutide, and it carries no approved brand name or indication. It remains classified as an unapproved research compound, meaning any use outside of registered clinical trials falls outside sanctioned medical practice.

Clinical trial footprint

Mazdutide has been registered in 37 clinical trials to date, reflecting an active but still developing research program. Early studies focused on basic human safety and tolerability, including "A Study of LY3305677 in Healthy Participants," which has completed, and a related multiple-dose study in healthy participants, also completed. More recent trial activity has expanded into specific disease populations, such as a currently recruiting study examining mazdutide (listed under the code IBI362) in participants with metabolic dysfunction-associated steatohepatitis (MASH). Together these trials show a research trajectory moving from initial human safety work toward studies in targeted patient groups, though no outcome data or approved use has been established.